Research Progress of mRNA Vaccines in Disease Prevention and Treatment
DOI:
https://doi.org/10.54097/wwwpxr92Keywords:
mRNA Vaccine, Molecular Structure, Synthesis and Purification, LNP Delivery System, Nucleoside Modification, Infectious Disease, Targeted Tumor Therapy, Nucleic Acid DeliveryAbstract
mRNA vaccine is a novel category in the medical field. Its core mechanism is to deliver mRNA into cells, and then use the host cell system to produce therapeutic proteins or immunogenic proteins, exerting therapeutic effects on the body or stimulating the body to produce antibodies. In addition to COVID-19, mRNA vaccines’ application in targeted tumor therapy is expanding, with numerous clinical trials underway. This review covers the molecular structure of mRNA vaccines, synthesis and purification technologies including nucleoside modification and LNP delivery systems, applications in infectious disease prevention and oncology treatment, and prospects for future development.
Downloads
References
[1] Saxena, S., Mandrah, V., Tariq, W., et al. (2025). The future of mRNA vaccines: Potential beyond COVID-19. Cureus, 17(5), e84529. https://doi.org/10.7759/cureus.84529.
[2] Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022). COVID-19 mRNA vaccines: Platforms and current developments. Molecular Therapy, 30(5), 1850–1868. https://doi.org/ 10. 1016/ j. ymthe.2022.03.036.
[3] Fang, E., Liu, X., Li, M., et al. (2022). Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy, 7(1), 94. https://doi.org/10.1038/s41392-022-00990-x.
[4] Gao, Y., Yang, L., Li, Z., et al. (2024). mRNA vaccines in tumor targeted therapy: Mechanism, clinical application, and development trends. Biomarker Research, 12(1), 93. https:// doi. org/10.1186/s40364-024-00623-7.
[5] Despic, V., & Jaffrey, S. R. (2023). mRNA ageing shapes the Cap2 methylome in mammalian mRNA. Nature, 614(7947), 358–366. https://doi.org/10.1038/s41586-022-05668-7.
[6] Gentry, R. C., Ide, N. A., Comunale, V. M., et al. (2025). The mechanism of mRNA cap recognition. Nature, 637(8046), 736–743. https://doi.org/10.1038/s41586-024-08291-7.
[7] Trepotec, Z., Geiger, J., Plank, C., et al. (2019). Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA, 25(4), 507–518. https://doi.org/ 10. 1261/ rna. 069913.118.
[8] Passmore, L. A., & Coller, J. (2022). Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nature Reviews Molecular Cell Biology, 23(2), 93–106. https://doi. org/ 10.1038/s41580-021-00417-7.
[9] Oh, A., Lee, S., Park, H. J., et al. (2025). Loop structure in poly(A) tail of mRNA vaccine enhances antigen translation efficiency and mRNA stability. npj Vaccines, 10(1), 234. https:// doi.org/10.1038/s41541-025-00882-3.
[10] Kormann, M. S., Hasenpusch, G., Aneja, M. K., et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 29(2), 154–157. https://doi.org/10.1038/nbt.1740.
[11] Fechter, P., & Brownlee, G. G. (2005). Recognition of mRNA cap structures by viral and cellular proteins. Journal of General Virology, 86(5), 1239–1249. https:// doi. org/ 10. 1099/ vir. 0. 80848-0.
[12] Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi. org/10. 1038/ nrd. 2017. 243.
[13] Webb, A. L. J., Welbourne, E. N., Evans, C. A., et al. (2025). Characterisation and analysis of mRNA critical quality attributes using liquid chromatography based methods. Journal of Chromatography A, 1745, 465724. https://doi.org/10. 1016/ j. chroma.2025.465724.
[14] Beverly, M., Dell, A., Parmar, P., et al. (2016). Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS. Analytical and Bioanalytical Chemistry, 408(18), 5021–5030. https://doi.org/10.1007/s00216-016-9601-6.
[15] Chen, H., Liu, D., Guo, J., et al. (2025). Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nature Biotechnology, 43(2), 194–203. https://doi.org/ 10. 1038/s41587-024-00782-4.
[16] Croce, S., Serdjukow, S., Carell, T., et al. (2020). Chemoenzymatic preparation of functional click-labeled messenger RNA. ChemBioChem, 21(11), 1641–1646. https:// doi. org/10.1002/cbic.202000136.
[17] Prabhakar, P. K., Khurana, N., Vyas, M., et al. (2023). Aspects of nanotechnology for COVID-19 vaccine development and its delivery applications. Pharmaceutics, 15(2), 451. https:// doi. org/ 10.3390/pharmaceutics15020451.
[18] Zong, Y., Lin, Y., Wei, T., et al. (2023). Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Advanced Materials, 35(51), e2303261. https://doi. org/ 10. 1002/ adma. 202303261.
[19] Knaggs, K. L. M., Sun, Y., Walz, B. A., et al. (2025). The role of excipients in lipid nanoparticle metabolism: Implications for enhanced therapeutic effect. Therapeutic Delivery, 16(7), 687–700. https://doi.org/10.1080/20415931.2025.2461238.
[20] Semple, S. C., Akinc, A., Chen, J., et al. (2010). Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 28(2), 172–176. https://doi.org/ 10. 1038/ nbt. 1608.
[21] Petrova, V. N., & Russell, C. A. (2018). The evolution of seasonal influenza viruses. Nature Reviews Microbiology, 16(1), 47–60. https://doi.org/10.1038/nrmicro.2017.118.
[22] Pierce, S. R., Shi, H., Caetano, C., et al. (2025). Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly reactive antibodies against seasonal influenza A viruses. Vaccine, 62, 127449. https://doi.org/10. 1016/j. vaccine. 2025.127449.
[23] Lee, I. T., Nachbagauer, R., Ensz, D., et al. (2023). Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: Interim analysis. Nature Communications, 14(1), 3631. https://doi.org/10.1038/s41467-023-38924-9.
[24] Cargnin Faccin, F., & Perez, D. R. (2024). Pandemic preparedness through vaccine development for avian influenza viruses. Human Vaccines & Immunotherapeutics, 20(1), 2347019. https://doi.org/10.1080/21645515.2024.2347019.
[25] Rojas, L. A., Sethna, Z., Soares, K. C., et al. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(7963), 144–150. https://doi.org/ 10.1038/s41586-023-06061-3.
[26] Lorentzen, C. L., Haanen, J. B., Met, Ö., et al. (2022). Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. The Lancet Oncology, 23(10), e450–e458. https://doi.org/10.1016/S1470-2045(22)00477-2.
[27] Dugdale, C. M., Ufio, O., Giardina, J., et al. (2025). Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: A systematic review and meta-analysis. The Lancet, 406(10501), 349–357. https://doi.org/10.1016/S0140-6736(25)01183-0.
[28] Doores, K. J. (2015). The HIV glycan shield as a target for broadly neutralizing antibodies. The FEBS Journal, 282(24), 4679–4691. https://doi.org/10.1111/febs.13563.
[29] Mu, Z., Haynes, B. F., & Cain, D. W. (2021). Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. Current Opinion in Virology, 51, 172–178. https://doi.org/10.1016/j.coviro.2021.101564.
[30] Zhou, T., Georgiev, I., Wu, X., et al. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329(5993), 811–817. https://doi. org/10. 1126/ science.1192819.
[31] Pardi, N., Secreto, A. J., Shan, X., et al. (2017). Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nature Communications, 8(1), 14630. https://doi. org/ 10. 1038/ncomms14630.
[32] Fang, Z., Yu, P., & Zhu, W. (2024). Development of mRNA rabies vaccines. Human Vaccines & Immunotherapeutics, 20(1), 2382499. https://doi.org/ 10.1080/ 21645515. 2024. 238 2499.
[33] Liu, J., Sun, J., Ding, X., et al. (2024). A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice. Emerging Microbes & Infections, 13(1), 2389115. https://doi.org/10.1080/22221751.2024.2389115.
[34] Wang, Y., Yu, T., Zhang, S., et al. (2025). A lyophilized anti-rabies mRNA-LNP vaccine induces early and robust immune responses from a single-dose subcutaneous administration. Veterinary Microbiology, 307, 110612. https://doi.org/ 10. 1016/ j. vetmic.2025.110612.
[35] Kaushik, M., Madeswaraguptha, P., Vanangamudi, M., et al. (2025). Recent progress, challenges (stability and in vivo distribution), and opportunities of DNA & mRNA vaccine in cancer immunotherapy. Advances in Immunology, 166, 211–258. https://doi.org/10.1016/bs.ai.2025.04.002.
[36] Shemesh, C. S., Hsu, J. C., Hosseini, I., et al. (2021). Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Molecular Therapy, 29(2), 555–570. https://doi.org/10.1016/j.ymthe.2020.12.035.
[37] Dalabehera, M., Ghosh, A., Mohanty, S., et al. (2025). mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics. Materials Today Bio, 35, 102584. https://doi.org/10.1016/j.mtbio.2025.102584.
[38] Sui, Y., Hou, X., Zhang, J., et al. (2025). Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy. Journal of Materials Chemistry B, 13(33), 10085–10117. https://doi.org/10.1039/D5TB00620A.
[39] Wang, Y., Ma, Q., Li, M., Mai, Q., Ma, L., Zhang, H., Zhong, H., Mai, K., Cheng, N., Feng, P., Guan, P., Wu, S., Zhang, L., Dai, J., Zhang, B., Pan, W., & Yang, Z. (2024). A decavalent composite mRNA vaccine against both influenza and COVID-19. mBio, 15(9), e00668-24. https://doi.org/ 10.1128/ mbio. 00668-24.
[40] Muodiaju, J. C., & Madu, C. S. (2025). Messenger ribonucleic acid (mRNA)-based universal vaccines: Engineering broad-spectrum immunity against future pandemics. Cureus, 17(5), e84821. https://doi.org/10.7759/cureus.84821.
[41] Sahin, U., Schmidt, M., Derhovanessian, E., et al. (2026). Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature, 651(8107), 1088–1096. https:// doi. org/ 10.1038/s41586-026-07401-7.
[42] Li, X., Jabbarzadeh Kaboli, P., Roozitalab, G., et al. (2026). Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy. Cell Oncology, 49(2), 72. https://doi.org/10.1007/s13402-025-01087-9.
[43] Srivastava, R. (2026). AI-powered mapping of tumor immunity for optimized mRNA vaccine engineering. Frontiers in Oncology, 16, 1766201. https://doi.org/ 10.3389/ fonc. 2026. 1766201.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
